Abstract 11090: Atorvastatin Reduces Uptakes of F-18 Fluorodeoxyglucose on Positron Emission Tomography Accumulation in Atherosclerotic Plaques
Objectives: Vascular inflammatory status would be an important factor to know plaque vulnerability. Recent studies have shown that F-18 fluorodeoxyglucose (18F-FDG) on positron emission tomography (PET) is an excellent tool for measuring local inflammatory level of atherosclerotic lesions. We examined effects of atorvastatin on F-18 fluorodeoxyglucose (18F-FDG) accumulations in atherosclerotic plaques by using positron emission tomography (PET).
Methods and Results: Thirty dyslipidemic patients without being treated with any kind of statins were enrolled and were randomly allocated to 5 mg/day atorvastatin group or 20 mg/day atorvastatin group. 18F-FDG uptakes in ascending aorta and femoral artery were examined by PET. After 6 months, both 5mg and 20mg atorvastatin reduced the mean target-to-Background ratio (TBR) uptake values in ascending aorta (−2.8%, P = 0.19 and −7.9%, P = 0.0071) and femoral artery (−1.9%, P = 0.46 and −9.9%, P = 0.012), respectively. However, the degree of TBR reduction did not statistically differ between the two dosage groups. When data from both dosage groups were mixed, statistically significant reduction in TBR was observed before and after atorvastatin treatment in examined arteries (P = 0.0033 in ascending aorta and P = 0.021 in femoral artery). In addition, the decrease in the TBR in those arteries was well correlated with reduction of total cholesterol (r = 0.401, P = 0.033 in ascending aorta and r = 0.598, P = 0.0018 in femoral artery), LDL cholesterol levels (r = 0.480, P = 0.012 in ascending aorta and r = 0.581, P = 0.0028 in femoral artery), MDA-LDL cholesterol levels (r = 0.428, P = 0.028 in ascending aorta and r = 0.497, P = 0.010 in femoral artery), and high sensitive CRP levels (r = 0.364, P = 0.048 in ascending aorta and r = 0.521, P = 0.0073 in femoral artery), respectively.
Conclusions: By using 18F-FDG-PET, 6-month treatment with atorvastatin significantly decreased TBR values on PET accumulation in atherosclerotic lesions in ascending and femoral artery in patients with dyslipidemia. The administration of atorvastatin attenuated inflammation in atherosclerotic plaques, and thereby plaque vulnerability.
- © 2010 by American Heart Association, Inc.